Comments to FDA: Evaluating Drug Names for Similarities; Methods and Approaches

Share page:

Letter | Jul 9, 2003

Docket Number:
2003N-0201

These comments are submitted in response to the public meeting of June 26 on evaluating drug names for similarities, which was co-sponsored by the FDA, PhRMA, and the Institute for Safe Medication Practices.

Related Posts

Press Releases and Statements

CHPA Welcomes Three Consumer Healthcare Industry Members

Press Releases and Statements

CHPA Statement: OTC Pain Relievers and COVID-19 Vaccines